Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessChina Lockdowns Weigh on Ambarella’s Near-Term Growth

China Lockdowns Weigh on Ambarella’s Near-Term Growth

Add to Favorite
Added to Favorite


Analysts at Berenberg Bank provided their views on Ambarella, Inc. (NASDAQ:AMBA), emphasizing the negative impact of China lockdowns on the company’s near-term revenue growth.
While the company reported a Q1 EPS beat last week, Q2 revenue guidance was approximately 13% below the Street estimates due to China lockdowns as customers deferred orders given difficulty securing components on their end.
With pandemic-related uncertainty in China and related supply-chain issues lingering, the company expects just a gradual quarter-over-quarter improvement in H2.
The analysts now assume 5% sales growth in 2022 (versus 17% previously) and reduce their price target to $150 from $185, while maintaining their buy rating as they think Street estimates are now “de-risked” and its valuation offers favorable risk/reward on reasonable estimates.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Thermo Fisher Scientific Reports Better Than Expected Q1 Results

Thermo Fisher Scientific (NYSE:TMO) announced its first-quarter earnings and...

Humana Drops 5 percent Despite Q1 Beat

Humana (NYSE:HUM) saw its shares drop by around 5%...

AT&T Reports Q1 EPS Beat, But Revenues Missed

AT&T (NYSE:T) reported its first-quarter earnings that exceeded analyst...